Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-02-07
2011-11-15
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S165000
Reexamination Certificate
active
08058294
ABSTRACT:
A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).
REFERENCES:
patent: 2653977 (1953-09-01), Craig et al.
patent: 3775477 (1973-11-01), Diana
patent: 4460581 (1984-07-01), Schromm et al.
patent: 5648370 (1997-07-01), Bonnert et al.
patent: 6686353 (2004-02-01), Shiota et al.
patent: 7700782 (2010-04-01), Connolly et al.
patent: 7709511 (2010-05-01), Bonnert et al.
patent: 2002/0055651 (2002-05-01), Moran et al.
patent: 2003/0229058 (2003-12-01), Moran et al.
patent: 2006/0106075 (2006-05-01), Cuenoud et al.
patent: 2008/0207698 (2008-08-01), Connolly et al.
patent: 2008/0242649 (2008-10-01), Cadogan et al.
patent: 2008/0249145 (2008-10-01), Whittock et al.
patent: 2008/0300275 (2008-12-01), Bonnert et al.
patent: 2009/0029958 (2009-01-01), Alcaraz et al.
patent: 2009/0062259 (2009-03-01), Alcaraz et al.
patent: 2009/0203753 (2009-08-01), Bailey et al.
patent: 2009/0221653 (2009-09-01), Bailey et al.
patent: 2010/0022491 (2010-01-01), Connolly et al.
patent: 2010/0210688 (2010-08-01), Bonnert et al.
patent: 2010/0249200 (2010-09-01), Connolly et al.
patent: 0162576 (1985-11-01), None
patent: 0174811 (1986-03-01), None
patent: 0175525 (1986-03-01), None
patent: 0220878 (1987-05-01), None
patent: 0303466 (1989-02-01), None
patent: 0422889 (1991-04-01), None
patent: 2005-187357 (2005-07-01), None
patent: 7415945 (1975-06-01), None
patent: WO 92/08708 (1992-05-01), None
patent: WO 93/23385 (1993-11-01), None
patent: WO 93/24473 (1993-12-01), None
patent: WO 97/10227 (1997-03-01), None
patent: WO 97/23470 (1997-07-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 98/38180 (1998-09-01), None
patent: WO 98/45294 (1998-10-01), None
patent: WO 99/36095 (1999-07-01), None
patent: WO 99/64035 (1999-12-01), None
patent: WO 00/75114 (2000-12-01), None
patent: WO 01/11933 (2001-02-01), None
patent: WO 01/12167 (2001-02-01), None
patent: WO 01/12191 (2001-02-01), None
patent: WO 01/12192 (2001-02-01), None
patent: WO 01/42193 (2001-06-01), None
patent: WO 02/06255 (2002-01-01), None
patent: WO 02/076933 (2002-10-01), None
patent: WO 03/024439 (2003-03-01), None
patent: WO 2004/016578 (2004-02-01), None
patent: WO 2004/016601 (2004-02-01), None
patent: WO 2004/039766 (2004-05-01), None
patent: WO 2004/071388 (2004-08-01), None
patent: WO 2004/074276 (2004-09-01), None
patent: WO 2004/089892 (2004-10-01), None
patent: WO 2005/030678 (2005-04-01), None
patent: WO 2005/040103 (2005-05-01), None
patent: WO 2005/044787 (2005-05-01), None
patent: WO 2005/070872 (2005-08-01), None
patent: WO 2005/074924 (2005-08-01), None
patent: WO 2005/092841 (2005-10-01), None
patent: WO 2005/092861 (2005-10-01), None
patent: WO 2005/092870 (2005-10-01), None
patent: WO 2005/110990 (2005-11-01), None
patent: WO 2005/111002 (2005-11-01), None
patent: WO 2005/111004 (2005-11-01), None
patent: WO 2005/121065 (2005-12-01), None
patent: WO 2006/014704 (2006-02-01), None
patent: WO 2006/023457 (2006-03-01), None
patent: WO 2006/023460 (2006-03-01), None
patent: WO 2006/031556 (2006-03-01), None
patent: WO 2006/056471 (2006-06-01), None
patent: WO 2006/074897 (2006-07-01), None
patent: WO 2006/128675 (2006-12-01), None
patent: WO 2007/010356 (2007-01-01), None
patent: WO 2007/018461 (2007-02-01), None
patent: WO 2007018461 (2007-02-01), None
patent: WO 2007/027133 (2007-03-01), None
patent: WO 2007/027134 (2007-03-01), None
patent: WO 2007/102771 (2007-09-01), None
patent: WO 2007/106016 (2007-09-01), None
patent: WO 2008/041914 (2008-04-01), None
patent: WO 2008/075025 (2008-06-01), None
patent: WO 2008/075026 (2008-06-01), None
patent: WO 2008/096111 (2008-08-01), None
patent: WO 2008/096112 (2008-08-01), None
patent: WO 2008/096119 (2008-08-01), None
patent: WO 2008/096121 (2008-08-01), None
patent: WO 2008/104776 (2008-09-01), None
patent: WO 2008/104790 (2008-09-01), None
patent: WO 2009/037503 (2009-03-01), None
M. Johnson Paediatric Respiratory Reviews 2001, 2, 57-62.
Schafer et al. (Drug Discovery Today 2008, 13 (21/22), 913-916).
Horig et al. Journal of Translational Medicine 2004, 2(44).
Austin et al. “QSAR and the Rational Design of Long-Acting Dual D2-Receptor/β2-Adrenoceptor Agonists” J. Med. Chem. 2003 46:3210-3220.
Berge et al. “Pharmaceutical Salts” J Pharmaceutical Sciences. 1977 66(1) 1-19.
Bonnert et al. “Dual D2-Receptor and β2-Adrenoceptor Agonists for the Treatment of Airway Diseases. 1. Discovery and Biological Evaluation of Some 7-(2-Aminoethyl)-4-hydroxybenzothiazol-2(3H)-one Analogues” J Med Chem. 1998 (41) 4915-4917.
Davies et al. “Indacaterol. Asthma Therapy Treatment of COPD β2-Adrenoceptor Agonist” Drugs of the Future. 2005 30(12) 1219-1224.
Dougall et al. “Dual dopamine D2receptor and β2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale” Respir Med (Suppl A). 2003 (97) S3-S7 (Abstract).
Fernández et al. “Alkaline Hydrolysis of 1,2,3-Trisubstituted Cyclic Amidinium Salts. Kinetic Study of N 4 N′ Acyl Migration in Alkaline Solution in an Ethylenediamine Derivative” J.C.S. Perkin II. 1978 545-550.
Fernández et al. “N 4 N′ Intramolecular Acyl Transfer in Acid Media for Alkylenediamine Derivatives” J.C.S. Perkin II. 1978 550-553.
Norman, “Which of three structures is AZD-3199? WO-2008104790, WO-2008096112 and WO-2008096119” Expert Opin. Ther. Patents. 2009 19(7) 1-7.
Weinstock et al. “Synthesis and Evaluation of Non-Catechol D-1 and D-2 Dopamine Receptor Agonists: Benzimidazol-2-one, Benzoxazol-2-one, and the Highly Potent Benzothiazol-2-one 7 Ethylamines” J Med Chem. 1987 (30) 1166-1176.
Wermuth et al., Handbook of Pharmaceutical salts: properties, selection and use, (2002) pp. 1-7: published by Wiley-VCH Verlag, ISBN: 10-3-906390-26-8.
Wright et al. “The Rearrangement ofN-(Methylamino-alkyl)anilides” J Org Chem. 1961 26(6) 2120-2123.
USPTO Non-Final Office Action in U.S. Appl. No. 11/959,679, mailed Feb. 25, 2009, 12 pages.
Fish & Richardson P.C., Amendment in Reply to Action of Feb. 25, 2009 in U.S. Appl. No. 11/959,679, filed Jul. 15, 2009, 6 pages.
USPTO Notice of Allowance in U.S. Appl. No. 11/959,679, mailed Nov. 9, 2009, 9 pages.
Fish & Richardson P.C., Response to Notice of Allowance mailed Nov. 9, 2009 in U.S. Appl. No. 11/959,679, filed Feb. 9, 2009, 2 pages.
USPTO Notice of Allowance in U.S. Appl. No. 12/063,322, mailed Feb. 26, 2010, 12 pages.
Fish & Richardson P.C., Response to Notice of Allowance mailed Feb. 26, 2010 in U.S. Appl. No. 12/063,322, filed Mar. 5, 2010, 2 pages.
USPTO Notice of Allowance in U.S. Appl. No. 12/065,160, mailed Jun. 15, 2010, 9 pages.
Chanez et al. “Corticosteroid reversibility in COPD is related to features of asthma” Am. J. Respir. Crit. Care Med. 1997 155(5) 1529-1534 (abstract only).
USPTO Non-Final Office Action in U.S. Appl. No. 12/027,424, mailed Mar. 8, 2011, 12 pages.
Fish & Richardson P.C., RCE/IDS in response to Notice of Allowance mailed Jun. 15, 2010 in U.S. Appl. No. 12/065,160, filed Sep. 15, 2010, 9 pages.
USPTO Non-Final Office Action in U.S. Appl. No. 12/282,634, mailed Aug. 5, 2010, 13 pages.
Fish & Richardson P.C., Amendment in Reply to Action of Aug. 5, 2010 in U.S. Appl. No. 12/282,634, filed Nov. 5, 2010, 18 pages.
USPTO Notice of Allowance in U.S. Appl. No. 12/282,634, mailed Jan. 24, 2011, 12 pages.
Swedish Search Report for Application No. PCT/SE2006/000927, dated Oct. 27, 2006, 8 pages.
European Search Report for Application No. PCT/GB2007/004861, dated Mar. 28, 2008, 4 pages.
Whittock Robert
Withnall Jane
AstraZeneca AB
Fish & Richardson P.C.
Nolan Jason M
LandOfFree
Pharmaceutical salts of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical salts of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical salts of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313158